<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although vitamin K2 is an inducer of the in vitro differentiation of myeloid leukemic cell lines, its clinical efficacy in the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is unclear </plain></SENT>
<SENT sid="1" pm="."><plain>We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to an 80-year-old woman with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo>) heavily dependent on red-cell transfusions </plain></SENT>
<SENT sid="2" pm="."><plain>The patient's <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> gradually improved, and she became transfusion-independent after 14 months </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001876'>Pancytopenia</z:hpo> recurred when menatetrenone was discontinued but recovered again with readministration </plain></SENT>
<SENT sid="4" pm="."><plain>Administration of menatetrenone at a dose effective in improving <z:hpo ids='HP_0000939'>osteoporosis</z:hpo> may also be useful in restoring hematopoiesis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, possibly by way of inducing differentiation </plain></SENT>
</text></document>